Study shows heart risks may return after stopping GLP-1 drugs
研究顯示，停止使用 GLP-1 藥物後心臟風險可能復發
更新於: 2026年9月22日 上午01:15
Recent findings published in BMJ Medicine highlight a crucial concern for patients using GLP-1 receptor agonists, such as semaglutide and tirzepatide.
近期發表於《英國醫學期刊醫學版》(BMJ Medicine) 的研究結果，突顯了使用 GLP-1 受體促效劑（如 semaglutide 與 tirzepatide）患者所面臨的關鍵問題。
While these medications are known to significantly reduce the risk of major cardiovascular events like heart attacks and strokes, a large-scale study of over 333,000 veterans suggests that these benefits are not permanent.
雖然已知這些藥物能顯著降低心臟病發作和中風等重大心血管事件的風險，但一項針對超過 33 萬 3 千名退伍軍人的大規模研究表明，這些益處並非永久性的。
The research indicates that heart protection begins to fade almost immediately after patients stop their treatment.
研究顯示，一旦患者停止治療，心臟保護作用幾乎立即開始消退。
Notably, the risk of cardiovascular events increases progressively: by two years post-discontinuation, the protective benefits are largely erased.
值得注意的是，心血管事件的風險會隨時間逐步增加：在停止用藥兩年後，保護效益已大致消失。
Experts emphasize that GLP-1 therapy should be viewed as a long-term, chronic commitment rather than a temporary solution.
專家強調，GLP-1 療法應被視為一種長期、慢性的承諾，而非暫時性的解決方案。
Although factors like high costs, side effects, and supply shortages often interrupt treatment, this study underscores the necessity of consistent adherence.
儘管高昂費用、副作用及藥物短缺等因素常導致治療中斷，但此研究強調了持續服藥的必要性。
Even if patients restart therapy later, the initial 'scars' on heart health may be difficult to fully reverse.
即使患者後來重新開始治療，心臟健康受到的初步「損害」可能難以完全逆轉。
Ultimately, these drugs provide vital heart benefits that extend beyond simple weight management, making long-term access and maintenance essential for high-risk patients.
最終，這些藥物提供了超越單純體重管理的關鍵心臟益處，使得長期獲取藥物與維持治療對於高風險患者而言至關重要。
